Private Trust Co. NA Buys 510 Shares of Edwards Lifesciences Co. (NYSE:EW)

Private Trust Co. NA increased its position in Edwards Lifesciences Co. (NYSE:EW) by 17.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,441 shares of the medical research company’s stock after purchasing an additional 510 shares during the period. Private Trust Co. NA’s holdings in Edwards Lifesciences were worth $255,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Wellington Management Group LLP lifted its stake in shares of Edwards Lifesciences by 86.3% in the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after buying an additional 14,610,123 shares in the last quarter. State Street Corp raised its holdings in Edwards Lifesciences by 1.0% in the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock worth $1,733,270,000 after acquiring an additional 256,538 shares during the last quarter. Geode Capital Management LLC raised its holdings in Edwards Lifesciences by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock worth $889,050,000 after acquiring an additional 284,918 shares during the last quarter. Fisher Asset Management LLC lifted its position in Edwards Lifesciences by 9.8% in the 3rd quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock valued at $599,078,000 after acquiring an additional 806,705 shares in the last quarter. Finally, Jennison Associates LLC purchased a new stake in Edwards Lifesciences during the 4th quarter valued at $555,939,000. Institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the sale, the chief financial officer now owns 30,561 shares in the company, valued at $2,315,301.36. The trade was a 26.91 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 37,739 shares of company stock valued at $2,799,104 over the last 90 days. Company insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Barclays boosted their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Canaccord Genuity Group upped their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research note on Thursday, February 13th. Truist Financial reaffirmed a “hold” rating and set a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Royal Bank of Canada reissued an “outperform” rating and set a $85.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Finally, Piper Sandler raised their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Price Performance

NYSE EW opened at $71.37 on Tuesday. The stock has a market cap of $42.09 billion, a price-to-earnings ratio of 10.24, a PEG ratio of 4.82 and a beta of 1.10. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company’s 50 day moving average is $72.58 and its two-hundred day moving average is $70.32. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.